Navigation Links
Statins Gives New Hope for Increased Survival Rate of Heart Failure Patients

Administrating statins to patients with diastolic heart failure increases// the survival rate by 22% compared to patients receiving other drugs.

William C. Little and his research team from Wake Forest University, has found that patients with diastolic heart failure (DHF) treated with statins has better survival rates. The study was done on 137 diastolic heart failure patients published in the Journal Circulation: Journal of the American Heart Association. Diastolic heart failure occurs as the heart does not fully relax and therefore does not fill properly with blood. The mortality occurring due to DHF is 5-8%. Once hospitalized, patients with diastolic heart failure have a 50 percent chance of re-hospitalization within six months. It’s estimated that the cost of treating patients for diastolic heart failure exceeds $3.5 billion a year.

William C. Little reports, "Some patients in the group had been diagnosed with high cholesterol and placed on statin therapy by their doctors. Others in the group whose cholesterol levels were not as high in general, were not placed on statins," Little and his research team found that during the study period, heart failure patients on statin therapy had a risk of death that was 22 percent lower than the patients receiving the other drugs. Even after adjusting for other factors that could have affected the results, such as hypertension or cardiovascular disease, the heart failure patients on statins still fared better.

The better survival of these patients is due to the beneficial effects of statins in DHF patients.

Source : (Newswise)

Further Information on Heart disease from Medindia

Chest pain is a common symptom which can be caused by many different conditions. Some causes of chest pain require prompt medical attention, such as angina, heart attack, or tearing of the aorta. Other causes of chest pain can be evaluated electively, such as spasm of the esophagus, gallbladder attack, or inflammation of the chest wall.

For more information:

http://www.medindia.net/patients/
patientinfo/chestpain_about.htm

'"/>




Related medicine news :

1. Statins reduce heart attacks
2. Statins reduce risks for angioplasty patients
3. Statins Found To Be Helpful For Patients With Arthritis
4. Long-Term Benefits Of Statins Questioned
5. Statins Not Effective In Treating Calcific Aortic Stenosis
6. The Effects of Statins Questioned
7. Statins Taken For Reducing Cholesterol Found To Reduce Death Rate Associated With Heart Attack As Well
8. Study Finds No Link Between Statins And Breast Cancer Risk
9. Statins Reduce Deaths And Strokes After Carotid Surgery
10. Statins reduces cardiovascular risk but no cancer risk.
11. Statins Prescribed To Those Who Are At a Risk Of Developing A Heart Disease
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/6/2016)... ... 06, 2016 , ... Experimentation involving human stem cells (HSCs) ... to its potential for revolutionizing human disease treatment. There are multiple HSC platforms ... cells (hiPSCs). , Both platforms have distinct advantages and disadvantages, but what ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... the much-anticipated HydroFX for Water®. This first-of-its-kind water-soluble powder supplement has a ... world’s most powerful antioxidants, molecular hydrogen, HydroFX for Water transforms every day ...
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... TopConsumerReviews.com recently ... Mobility Scooters . , Mobility Scooters give freedom to people who need help ... Still others may be facing a long period of rehabilitation after an illness or ...
(Date:12/5/2016)... ... December 05, 2016 , ... "FCPX Overlay Glare is ... natural lighting effect without heavy rendering or complicated compositing," said Christina Austin - CEO ... to create an organic spectrum of lights that simulates the look of a glare. ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... and relationship-marketing firm, announced today that nominations will be accepted from December ... (ISE®) Central Awards. , Awards include the Information Security Executive® of the ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... CRANBURY, N.J. , Dec. 5, 2016 /PRNewswire/ ... pharmaceutical company, today presented data from two Phase ... poster sessions at the 58th annual meeting of ... San Diego, California . The two ... patients with acute myeloid leukemia (AML) and T-cell ...
(Date:12/5/2016)... Dec. 5, 2016   Lexicon Pharmaceuticals, Inc. ... from a Phase 2 clinical study of sotagliflozin, a ... collaboration with JDRF, the leading global organization funding type ... Phase 2 clinical trial, which randomized a total of ... once-daily 400 mg dose of sotagliflozin compared to a ...
(Date:12/5/2016)... 5, 2016  Sharn Anesthesia Inc. announced today that ... distribution partner for Salter Labs.  The company also received ... recognition of outstanding sales performance. Salter Labs ... anesthesia care, including the market gold standard ECO 2 ... distributor of the Parker Flex-Tip® Endotracheal Tube, which is ...
Breaking Medicine Technology: